This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Original articles
Forssen EA, Tökeé ZA: Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. Cancer Treat Rep 67: 481–484, 1983.
Madhavan S, Northfelt DW: Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst 87: 1556–1557, 1995.
Balazsovits JA, Mayer LD, Bally MB, et al: Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23: 81–86, 1989.
Schmidmair M: personal communication, May 1999.
Secondary literature
van Gemmern R: Gewebstoxizität and Paravasatbehandlung neuer Zytostatika. Krankenhauspharmazie 17: 471–473, 1996.
Dezube BJ: Safety assessment: Doxil® (doxorubicin HC1 liposome injection) in refractory AIDS-related Kaposi’s sarcoma. Doxil Clinical Series 1: 1–7, 1997.
Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.
Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.
Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P.E., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2003). Doxorubicin liposomal. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3710-9_23
Download citation
DOI: https://doi.org/10.1007/978-3-7091-3710-9_23
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-3712-3
Online ISBN: 978-3-7091-3710-9
eBook Packages: Springer Book Archive